For example, for colorectal cancer, the chemotherapy regimens used in the trials included are now anachronistic, as the triple regimen FOLFOXIRI (fluorouracil, oxaliplatin, and irinotecan) in combination with EGFR and VEGFR inhibitors have dramatically changed the prognosis of this disease.31 Third, all studies were of limited quality, as 3 out of 4 RCTs showed some concerns in risk of bias assessment, and the retrospective study had a moderate risk of bias. This evidence concerns the gene EGFR and colorectal cancer.